Speaker Profile
Ph.D., Professor, Hebrew U.
Biography
Professor Tabach leads the Deep Genomics Laboratory at the Hebrew University Medical School and is the founder of three companies specializing in genomics, cancer, and genetic diseases. He earned his PhD from the Weizmann Institute in systems biology and cancer, followed by postdoctoral training at Harvard Medical School in Professor Ruvkun’s lab, where he uncovered small-RN Ai pathways and mechanisms underlying genetic diseases by developing multi-omics methodologies.
His research identifies novel drug targets that reveal cancer vulnerabilities by deciphering the exceptional responder phenomenon- rare stage-IV patients who experience remarkable tumor regression - enabling the selective elimination of cancer cells while minimizing harm to healthy tissue.
Through both academic work and entrepreneurial initiatives, Professor Tabach develops innovative solutions for cancer, aging, and genetic diseases by translating animal “super-traits” into RNA-based therapies for humans. His functional genomics discoveries have revealed key disease pathways and cancer genes, significantly advancing drug discoveries and personalized treatment.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
